Arcutis Completes Enrollment in INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis
August 04, 2022 08:00 ET
|
Arcutis Biotherapeutics, Inc.
A total of 654 adults and children, age six and older, have been enrolled in the INTEGUMENT-1 trialEnrollment continues in INTEGUMENT-2 with topline data from both trials expected by end of 2022Atopic...
Arcutis Biotherapeutics Announces Pricing of Public Offering of Common Stock
August 02, 2022 21:27 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing...
Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock
August 02, 2022 16:02 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing...
Arcutis to Host Investor Conference Call Today to Discuss the FDA Approval of ZORYVE™ (roflumilast) Cream 0.3% for Plaque Psoriasis
August 01, 2022 07:30 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial biopharmaceutical company focused on developing meaningful...
Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis
June 06, 2022 07:30 ET
|
Arcutis Biotherapeutics, Inc.
Study met its primary endpoint with 80.1% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared to 59.2% of patients treated with vehicle...
CORRECTION: Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care
May 25, 2022 10:33 ET
|
Arcutis Biotherapeutics, Inc.
Seborrheic dermatitis is a chronic, inflammatory skin disease that affects more than 10 million people in the U.S.Survey found that, among adults with seborrheic dermatitis who use treatments, only...
Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update
May 05, 2022 16:01 ET
|
Arcutis Biotherapeutics, Inc.
Increasing commercial preparations in advance of our Prescription Drug User Fee Act (PDUFA) action date of July 29, 2022 for roflumilast cream for the treatment of plaque psoriasis in adults and...
Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis
April 06, 2022 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Topline data anticipated in late Q3/early Q4A total of 432 subjects are enrolled in the ARRECTOR studyArcutis progressing topical roflumilast in four dermatological indicationsOver 3 million patients...
Arcutis Highlights Growth Opportunities at Investor Day in Advance of 2022 Catalysts
March 28, 2022 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Differentiated profile of topical roflumilast aligned with unmet needs in multiple inflammatory dermatosesWell-prepared for the Company’s potential first launch ahead of PDUFA target action date of...
Arcutis to Host Investor Day on March 28
March 21, 2022 08:00 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...